Russell Investments Group Ltd. grew its position in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 1,121.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 108,834 shares of the company's stock after purchasing an additional 99,923 shares during the period. Russell Investments Group Ltd. owned approximately 0.18% of Twist Bioscience worth $4,273,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of TWST. Farther Finance Advisors LLC grew its holdings in Twist Bioscience by 18.5% during the first quarter. Farther Finance Advisors LLC now owns 6,435 shares of the company's stock worth $251,000 after acquiring an additional 1,006 shares during the period. GAMMA Investing LLC grew its holdings in Twist Bioscience by 6,499.1% in the first quarter. GAMMA Investing LLC now owns 29,366 shares of the company's stock valued at $1,153,000 after purchasing an additional 28,921 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new stake in Twist Bioscience in the first quarter valued at approximately $396,000. SG Americas Securities LLC acquired a new stake in Twist Bioscience in the first quarter valued at approximately $893,000. Finally, Wells Fargo & Company MN grew its holdings in Twist Bioscience by 34.5% in the fourth quarter. Wells Fargo & Company MN now owns 37,886 shares of the company's stock valued at $1,761,000 after purchasing an additional 9,722 shares during the period.
Insider Buying and Selling
In related news, CFO Adam Laponis sold 2,449 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total transaction of $93,429.35. Following the transaction, the chief financial officer owned 103,569 shares in the company, valued at approximately $3,951,157.35. This trade represents a 2.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Emily M. Leproust sold 1,678 shares of Twist Bioscience stock in a transaction on Friday, June 20th. The shares were sold at an average price of $35.76, for a total value of $60,005.28. Following the completion of the sale, the chief executive officer owned 645,782 shares in the company, valued at $23,093,164.32. This represents a 0.26% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,250 shares of company stock worth $193,852. 3.01% of the stock is currently owned by company insiders.
Twist Bioscience Stock Performance
Shares of Twist Bioscience stock opened at $28.59 on Friday. Twist Bioscience Corporation has a one year low of $24.28 and a one year high of $55.33. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -19.72 and a beta of 2.36. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. The business's 50 day moving average price is $33.54 and its 200 day moving average price is $36.41.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.The firm had revenue of $96.06 million for the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, research analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.
Wall Street Analysts Forecast Growth
TWST has been the topic of several research reports. Cowen restated a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Evercore ISI set a $46.00 target price on Twist Bioscience in a research report on Monday, August 4th. JPMorgan Chase & Co. decreased their target price on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Robert W. Baird decreased their target price on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Finally, The Goldman Sachs Group decreased their target price on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Twist Bioscience currently has a consensus rating of "Moderate Buy" and an average target price of $49.40.
Check Out Our Latest Stock Report on Twist Bioscience
Twist Bioscience Profile
(
Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Twist Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.
While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access